Adding triamcinolone improves viscosupplementation: a randomized clinical trial
Clin Orthop Relat Res. 2013 Feb;471(2):613-20. doi: 10.1007/s11999-012-2659-y. Epub 2012 Oct 2
6
- Population: 104 patients with knee osteoarthritis and randomized them to receive
- Intervention: single intraarticular injection (6 mL) of hylan GF-20 (Group viscosupplementation [Group VS])
- Control: single intraarticular injection of hylan GF-20 (6 mL) and 1 mL (20 mg) of triamcinolone hexacetonide (Group VS + T)
- Outcome Measures: VAS, WOMAC™, and Lequesne questionnaires were completed at baseline and at Weeks 1, 4, 12, and 24.
Results:
- At Week 1 the WOMAC and VAS scores were lower in Group VS + T, compared with Group VS. There was no difference regarding the adverse effects. At Weeks 4, 12, and 24 there were no differences in the groups.
Conclusion:
- The addition of triamcinolone hexacetonide improves first-week symptom and functional scores of viscosupplementation, but not beyond. It does not seem to increase the likelihood of adverse effects.
Ref:
1. http://link.springer.com/article/10.1007%2Fs11999-012-2659-y
Leave a Reply